These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20865632)

  • 1. Hemolytic uremic syndrome. Foreword.
    Würzner R; Zimmerhackl LB
    Semin Thromb Hemost; 2010 Sep; 36(6):571-2. PubMed ID: 20865632
    [No Abstract]   [Full Text] [Related]  

  • 2. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation in atypical hemolytic uremic syndrome.
    Kavanagh D; Richards A; Goodship T; Jalanko H
    Semin Thromb Hemost; 2010 Sep; 36(6):653-9. PubMed ID: 20865642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.
    Taylor CM; Machin S; Wigmore SJ; Goodship TH;
    Br J Haematol; 2010 Jan; 148(1):37-47. PubMed ID: 19821824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab for congenital atypical hemolytic-uremic syndrome.
    Gruppo RA; Rother RP
    N Engl J Med; 2009 Jan; 360(5):544-6. PubMed ID: 19179329
    [No Abstract]   [Full Text] [Related]  

  • 6. Skin involvement in atypical hemolytic uremic syndrome.
    Ardissino G; Tel F; Testa S; Marzano AV; Lazzari R; Salardi S; Edefonti A
    Am J Kidney Dis; 2014 Apr; 63(4):652-5. PubMed ID: 24290245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the management of atypical hemolytic uremic syndrome.
    Cataland SR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):537-9. PubMed ID: 23073053
    [No Abstract]   [Full Text] [Related]  

  • 8. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
    Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
    N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
    Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
    Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab for atypical hemolytic-uremic syndrome.
    Nürnberger J; Philipp T; Witzke O; Opazo Saez A; Vester U; Baba HA; Kribben A; Zimmerhackl LB; Janecke AR; Nagel M; Kirschfink M
    N Engl J Med; 2009 Jan; 360(5):542-4. PubMed ID: 19179328
    [No Abstract]   [Full Text] [Related]  

  • 11. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.
    Prescott HC; Wu HM; Cataland SR; Baiocchi RA
    Am J Hematol; 2010 Dec; 85(12):976-7. PubMed ID: 20941783
    [No Abstract]   [Full Text] [Related]  

  • 12. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.
    Cañigral C; Moscardó F; Castro C; Pajares A; Lancharro A; Solves P; de la Rubia J; Carpio N; Sanz MA
    Ann Hematol; 2014 Aug; 93(8):1421-2. PubMed ID: 24306089
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful discontinuation of eculizumab therapy in a patient with aHUS.
    Pu JJ; Sido A
    Ann Hematol; 2014 Aug; 93(8):1423-5. PubMed ID: 24346709
    [No Abstract]   [Full Text] [Related]  

  • 14. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome.
    Tsai HM
    Am J Med; 2013 Mar; 126(3):200-9. PubMed ID: 23410558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More on eculizumab for congenital atypical hemolytic-uremic syndrome.
    Shin JI; Lee JS
    N Engl J Med; 2009 May; 360(20):2142-3; author reply 2143. PubMed ID: 19439754
    [No Abstract]   [Full Text] [Related]  

  • 16. The complement system in hemolytic-uremic syndrome in childhood.
    Monnens L; Molenaar J; Lambert PH; Proesmans W; van Munster P
    Clin Nephrol; 1980 Apr; 13(4):168-71. PubMed ID: 7379368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.
    Larrea CF; Cofan F; Oppenheimer F; Campistol JM; Escolar G; Lozano M
    Transplantation; 2010 Apr; 89(7):903-4. PubMed ID: 20386298
    [No Abstract]   [Full Text] [Related]  

  • 18. [Plasma exchange as therapy of recurrent hemolytic-uremic syndrome (HUS) in adults].
    Jockenhövel F; Grandt D; Weber F; Fritschka E; Philipp T
    Med Klin (Munich); 1991 Aug; 86(8):419-22. PubMed ID: 1921910
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside.
    Orth-Höller D; Riedl M; Würzner R
    EMBO Mol Med; 2011 Nov; 3(11):617-9. PubMed ID: 21954211
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on evaluating complement in hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):565-71. PubMed ID: 18089972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.